Loading...
XJPX2929
Market cap177mUSD
Jan 21, Last price  
985.00JPY
1D
0.72%
1Q
12.70%
Jan 2017
136.21%
IPO
72.81%
Name

Pharma Foods International Co Ltd

Chart & Performance

D1W1MN
XJPX:2929 chart
P/E
8.62
P/S
0.44
EPS
114.28
Div Yield, %
2.54%
Shrs. gr., 5y
-0.42%
Rev. gr., 5y
42.62%
Revenues
62.15b
-9.37%
810,836,000734,098,000959,103,0001,006,661,0001,225,029,0001,524,506,0001,614,558,0002,165,708,0003,460,766,0004,722,596,0007,943,262,00010,532,834,00015,353,384,00046,752,000,00060,185,000,00068,572,000,00062,147,000,000
Net income
3.21b
+4.02%
-455,017,000-207,576,00015,246,000-46,602,00060,034,000269,346,0008,831,000-187,887,00025,896,000101,310,000313,661,000499,849,000690,000,0003,841,000,000-374,000,0003,081,000,0003,205,000,000
CFO
5.49b
-10.43%
-139,662,000-129,344,000-32,823,000-18,782,000179,261,00016,763,000-218,500,000-242,112,000-35,298,000233,853,000415,543,00090,655,000-547,064,0005,938,000,000-6,065,000,0006,125,000,0005,486,000,000
Dividend
Jan 30, 20250 JPY/sh

Profile

Pharma Foods International Co., Ltd. engages in the development and sale of functional food ingredients in Japan. Its products include Pharma-GABA, Bonepep, Ovopron (egg yolk globulin), Delicious Catechin, RunPep, and enriched Folic Acid Egg, as well as iHA, a substance that stimulates secretion of hyaluronic acid. Pharma Foods International Co., Ltd. has licensing agreement with Mitsubishi Tanabe Pharma Corporation for a new therapeutic antibody to treat autoimmune diseases. Pharma Foods International Co., Ltd. was founded in 1997 and is based in Kyoto, Japan.
URL
https://www.pharmafoods.co.jp/
IPO date
Jun 12, 2006
Employees
624
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑072023‑072022‑072021‑072020‑072019‑072018‑072017‑072016‑072015‑07
Income
Revenues
62,147,000
-9.37%
68,572,000
13.94%
60,185,000
28.73%
Cost of revenue
56,934,000
57,094,000
52,003,000
Unusual Expense (Income)
NOPBT
5,213,000
11,478,000
8,182,000
NOPBT Margin
8.39%
16.74%
13.59%
Operating Taxes
1,828,000
462,000
1,797,000
Tax Rate
35.07%
4.03%
21.96%
NOPAT
3,385,000
11,016,000
6,385,000
Net income
3,205,000
4.02%
3,081,000
-923.80%
(374,000)
-109.74%
Dividends
(626,000)
(578,000)
(871,000)
Dividend yield
2.00%
1.19%
2.05%
Proceeds from repurchase of equity
(999,000)
(298,000)
(294,000)
BB yield
3.19%
0.62%
0.69%
Debt
Debt current
15,660,000
14,291,000
16,160,000
Long-term debt
1,231,000
1,763,000
718,000
Deferred revenue
Other long-term liabilities
594,000
476,000
595,000
Net debt
(2,347,000)
(2,766,000)
8,080,000
Cash flow
Cash from operating activities
5,486,000
6,125,000
(6,065,000)
CAPEX
(973,000)
(405,000)
(472,000)
Cash from investing activities
(1,390,000)
(1,013,000)
(2,539,000)
Cash from financing activities
(4,842,000)
2,341,000
7,679,000
FCF
3,159,000
13,634,000
(3,698,000)
Balance
Cash
15,666,000
16,306,000
8,845,000
Long term investments
3,572,000
2,514,000
(47,000)
Excess cash
16,130,650
15,391,400
5,788,750
Stockholders' equity
10,965,000
8,159,000
5,390,000
Invested Capital
18,105,000
22,054,000
18,700,000
ROIC
16.86%
54.06%
54.44%
ROCE
17.93%
37.99%
33.96%
EV
Common stock shares outstanding
28,441
28,877
29,014
Price
1,101.00
-34.31%
1,676.00
14.48%
1,464.00
-49.46%
Market cap
31,313,578
-35.30%
48,397,022
13.94%
42,476,250
-49.56%
EV
28,966,578
45,631,022
50,558,250
EBITDA
6,120,000
12,024,000
8,702,000
EV/EBITDA
4.73
3.79
5.81
Interest
62,000
48,000
26,000
Interest/NOPBT
1.19%
0.42%
0.32%